News in brief - November 2014

Other new launches, licence changes and updates relevant to general practice.

Glycopyrronium bromide is an anticholinergic that diminishes the volume and free acidity of gastric secretions.
Glycopyrronium bromide is an anticholinergic that diminishes the volume and free acidity of gastric secretions.
  • Glycopyrronium bromide 1mg and 2mg tablets are now available as an add-on treatment for peptic ulcers.
  • GranuPAS (para-aminosalicylic acid) has been launched for use in combination with other drugs to treat multidrug-resistant TB where other agents cannot be used owing to resistance or intolerance.
  • A new controlled-release misoprostol vaginal delivery system (Mysodelle) has been launched for the induction of labour from 36 weeks' gestation in women with an unfavourable cervix.
  • Dexamethasone 4mg/ml injection has been replaced by dexamethasone 3.8mg/ml solution for injection; as a result, the dilutions, storage conditions, presentation and packaging have changed.
  • Novartis has announced the discontinuation of Tegretol Chewtabs (carbamazepine). Selection of an alternative medication should be a clinical decision based on the individual patient's history.

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Third tiotropium inhaler adds to treatment options for COPD patients

Third tiotropium inhaler adds to treatment options for COPD patients

Tiogiva is a new breath-actuated inhaler containing...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

New shingles vaccine awaits decision on NHS use

New shingles vaccine awaits decision on NHS use

Shingrix, which is now available privately in the UK,...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...